Completed PHASE4 INTERVENTIONAL 2-arm NCT00134745

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

The Growth of Genitalia Interna and the Bone Mineralization Under Hormonal Replacement Therapy and the Presence of Aortic Root Dilatation in Girls With Turner Syndrome

Sponsor: Line Cleemann

Conditions Turner Syndrome

Interventions estradiol

Updated 6 times since 2017 Last updated: Jun 13, 2013 Started: Jun 30, 2005 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Turner Syndrome and is currently completed. Line Cleemann leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Line Cleemann
Novo Nordisk A/S
The County of Frederiksborg
The foundation of Kaptajnløjtnant Harald Jensen and Wife
The foundation of Mr. Ivan Nielsen
The foundation of Mrs. Olga Bryde

Data source: Hillerod Hospital, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hillerød, Denmark